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ABSTRACT
Background. The prognostic significance of size of cen-
tral lymph node metastasis (CLNM) in papillary thyroid
carcinoma (PTC) remains unknown. Because postsurgical
detectable stimulated thyroglobulin (DsTg) after radioio-
dine ablation may imply persistent or recurrent disease, we
evaluated the association between size of CLNM and rate
of DsTg in patients with PTC who underwent unilateral
prophylactic central neck dissection.
Methods. To be eligible for analysis, the prophylactic cen-
tral neck dissection specimen with \3 central lymph nodes
(CLNs) or size of CLNM C1 cm as measured under the
microscope was excluded. Of 132 specimens, 89 (67.4 %)
were eligible. Forty patients (44.9 %) had no metastasis or
pN0, 20 (22.5 %) had micrometastasis (\2 mm) or pN1mic
and 29 (32.6 %) had macrometastasis (C2 mm) or pN1mac.
Postablation sTg level was measured 9 months after surgery.
A multivariable analysis was conducted to identify indepen-
dent factors for postablation DsTg.
Results. Larger-sized CLNM correlated significantly with
younger age (p = 0.028), greater number of CLN retrieved
(p = 0.016), greater number of metastatic CLN excised
(p \ 0.001), higher metastatic CLN ratio (p = 0.006) and
postablation sTg level (p = 0.012). In the multivariable
analysis, after adjusting for tumor size and metastatic CLN
ratio, size of CLNM was an independent predictor of
postablation DsTg (odds ratio 1.56, 95 % confidence
interval 1.09–2.24, p = 0.015). Relative to pN0, the odds
ratios for postablation DsTg in pN1mic and pN1mac were
2.53 (95 % confidence interval 0.35–19.00, p = 0.351) and
5.81 (95 % confidence interval 1.22–27.70, p = 0.027),
respectively.
Conclusions. Size of CLNM was an independent factor
for DsTg 9 months after surgery. Patients with pN1mac
were almost 6 times more likely to have postablation DsTg
than those with pN0 or pN1mic.
Papillary thyroid carcinoma (PTC) is the most common
type of differentiated thyroid carcinoma, and its age-
adjusted incidence has doubled in the last 25 years.1
Despite its relatively good prognosis, with a cancer-specific
survival above 90 %, locoregional recurrence (LRR) is
common.2 With recognition of the stepwise progression of
lymph node metastasis (LNM) originating from the central
(level VI) to the lateral compartment (levels II–V), a
growing number of surgeons are advocating routine pro-
phylactic central neck dissection (pCND) at the time of the
total thyroidectomy.3 Although the role of pCND has
remained controversial because there is little evidence to
suggest that it improves long-term outcomes when com-
pared to no pCND, analysis of short-term markers (such as
stimulated thyroglobulin) (sTg) seems to suggest pCND
may improve short-term outcomes.4–7
Because patients with clinically apparent or palpable
LNM in the lateral compartment (or N1b) are at signifi-
cantly higher risk of developing LRR and distant
metastases when compared to those with clinically inap-
parent LNM, size of LNM is believed to be a prognostic
factor in patients with PTC.8–14 However, to our knowl-
edge, no study has specifically addressed the significance
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of size of central LNM (CLNM) in patients who routinely
undergo pCND. For patients who undergo pCND after total
thyroidectomy, the incidence of histologically proven
CLNM ranged 40–50 %.4–7 However, because these
CLNM are often small in size and may only be seen under
high-power magnification, their clinical significance have
been questioned.12,13 A recent study reported a series of 72
patients who underwent a pCND and found that none had
CLNM C2 mm in size (macrometastasis or pN1mac),
whereas only 18 patients (25.0 %) had CLNM \2 mm
(micrometastasis or pN1mic) present in the central lymph
nodes (CLNs).15 We hypothesized that size of CLNM
might have a negative impact on prognosis, with larger
CLNM leading to poorer prognosis. Postsurgical detectable
sTg level (DsTg) after radioiodine (RAI) ablation is a good
surrogate for persistent or recurrent disease after total
thyroidectomy.16–19 Therefore, the present study aimed to
evaluate the association between size of CLNM and rate of
postablation DsTg in patients who underwent an unilateral
pCND with particular emphasis on the incidence and sig-
nificance of pN1mic and pN1mac.
PATIENTS AND METHODS
From 2005 to 2011, a total of 250 consecutive patients
with PTC underwent surgery in our institution. All were
managed by the same surgical team. Of these, 142 (56.8 %)
underwent a routine unilateral pCND at the time of the
total thyroidectomy. None had evidence of CLNM preop-
eratively on ultrasonography or intraoperatively. Patients
with concomitant lateral lymph node metastases (N1b) or
distant metastases (M1) were excluded. All operations
were performed by two endocrine surgeons. The decision
for a prophylactic unilateral central neck dissection
(pCND) was based on the personal preference of the
operating surgeon and not based on tumor size or other
tumor characteristics. However, there was a tendency to
perform more pCND in the latter part of the study period.
During the study period, all resected specimens were
examined by the same group of pathologists in our insti-
tution by a standardized technique. Specimens containing
\3 CLNs retrieved during pCND (n = 38) were excluded
to reduce the possibility of nodal under-staging.20 Also,
patients with anti-thyroglobulin (Tg) autoantibody titer of
[400 (n = 10) were excluded. Therefore, a total of 94
patients were eligible for analysis. Of these, 40 (42.6 %)
had no demonstrable LNM on hematoxylin and eosin stain
(or pN0) (group I), whereas 54 (57.4 %) had C1 demon-
strable metastatic focus in CLN on hematoxylin and eosin
stain. To measure the size of the CLNM, the relevant slides
were retrieved and reexamined by two independent
pathologists (A.H.T., T.W.S.). All metastatic foci were
measured to the nearest tenth of a millimeter with a built-in
computerized measurement program on the microscope
(Nikon Eclipse E600). For patients with multiple metastatic
foci, only the largest microscopic focus was recorded. To
further ensure that the study only evaluated the significance
of size of CLNM in the prophylactic setting, 5 patients with
CLNM C1 cm were excluded because they could not be
considered as prophylactic. To evaluate the association
between size of CLNM and other clinicopathologic char-
acteristics, patients were categorized into 3 groups: group I
(pN0) (n = 40), group II (size of CLNM \2 mm)
(pN1mic) (n = 20) and group III (size of CLN metastasis
C2 mm) (pN1mac) (n = 29).
METHODS
All relevant clinical, laboratory, radiologic and periop-
erative data were collected prospectively, and follow-up
data were regularly updated in a computerized database.
The present study protocol was approved by the local
institutional review board. Patient clinicopathologic fea-
tures, sTg and postoperative outcomes were compared
between the three groups.
Management of PTC
Details of surgical treatment, criteria for RAI ablation,
postoperative care and follow-up protocol have been
described previously.11 In brief, total thyroidectomy was
the preferred procedure for all patients with a preoperative
diagnosis of PTC. A similar extent of unilateral pCND was
performed for all patients, regardless of tumor size or
extent.6 The pCND consisted of the removal of all nodes
and fibro-fatty tissue extending vertically from the hyoid
bone to the thoracic inlet and laterally from the medial
border of common carotid artery to the midline of the
trachea. The ipsilateral recurrent laryngeal nerve was
mobilized and skeletonized along its entire cervical course.
Parathyroid autotransplantation was readily performed. sTg
was defined as a Tg level measured in the presence of
thyroid-stimulating hormone (TSH) [30 mIU/L either by
4-week thyroxine withdrawal or recombinant TSH injec-
tions. The preablation sTg levels were taken approximately
2 months after surgery (at the time of RAI ablation), while
the postablation levels were taken approximately 9 months
after surgery (6–7 months after RAI ablation or at the time
of the whole body scan). Tg autoantibodies were measured
at the same time. The decision for RAI ablation was based
on the presence of at least one or more risk factors such as
tumor size [1 cm, LNM, age older than 45 years, extra-
thyroidal extension, macroscopic postoperative residual
disease in the neck and distant metastasis, and were not
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dependent on the preablative sTg level. Three giga bec-
querels or 80 mCi I131 was the standard dose. TSH
suppression to \0.1 lg/L was recommended for high- and
intermediate-risk patients.
Follow-up Protocol
All postsurgical patients were followed up within
4 weeks in a specialized combined oncology clinic. A
follow-up visit was conducted at 3-month intervals in the
first 2 years, every 6 months in the subsequent 3 years, and
annually thereafter. Clinical examination, neck ultraso-
nography and nonstimulated Tg level were done during
follow-up visits. LRR was confirmed by fine-needle aspi-
ration cytology or histology.
Laboratory Methods
All postoperative sTg levels were measured at the same
laboratory by the same immunometric assay. The assay used
was Immulite 2000 (Diagnostic Products, Roche, Los Angeles,
CA). This was calibrated against the CRM-457 standard. A sTg
level of C0.5 lg/L was considered a detectable stimulated
thyroglobulin (DsTg). Normal reference range was \0.5–
55 lg/L, and sensitivity was\0.2 lg/L).
Statistical Analyses
Statistical analyses was performed by v2 or Fisher’s
exact test to compare categorical variables, and Mann–
Whitney U or Kruskal–Wallis test was used to compare
continuous variables between groups. To evaluate the
correlation between two continuous variables, the Spear-
man rank correlation test was performed. Continuous
variables were expressed as medians with ranges. Variables
that were significant in the univariate analysis were entered
into multivariate analysis. Binary logistic regression anal-
ysis with a variable entrance criterion of 0.05 or less was
conducted to identify factors associated with postablative
DsTg after surgery. Disease-free survivals were estimated
by the Kaplan–Meier method and compared with the log-
rank test (Fig. 1). All statistical analyses were performed
by SPSS software, version 18.0 (SPSS, Chicago, IL).
RESULTS
In our cohort, most were women (75.3 %) and ethnic
Chinese (89.9 %). The median age at operation was 48.0
(range 8.1–81.3) years, and the median follow-up period
was 29.1 (range 9.3–90.1) months. The median primary
tumor size was 1.5(range 0.3–6.0) cm, with 8 (9.0 %)
being microcarcinomas (\1 cm). The median number of
metastatic CLNs was 1 (range 1–18), and the median
number of CLNs collected was 6 (range 3–21). The median
size of CLNM was 2.6 (range 0.1–6.9) mm.
Table 1 shows a comparison of patient clinicopathologic
features, tumor, node, metastasis staging system (TNM)
tumor stages, CLN ratio, and metastases, age, complete-
ness of surgery, invasion, and size (MACIS) score between
the three groups. The median age at operation was signif-
icantly different between the three groups (p = 0.003),
with group III having the youngest median age of
43.0 years. There was an inverse correlation between age
and size of CLNM (q = -0.315, p = 0.028). Gender,
clinical presentation and tumor characteristics such as
tumor size, multifocality, capsular invasion, extrathyroidal
extension and coexisting thyroiditis were not significantly
different between the three groups. Stage of PTC by TNM,
MACIS score, postoperative complications and anti-Tg
autoantibody titer were also similar between the three
groups. Group III had significantly higher number of
CLNs retrieved (p = 0.007), metastatic CLNs excised
(p \ 0.001) and metastatic CLN ratio (p = 0.010) than the
other two groups. There was a direct correlation between
size of CLNM and number of CLNs retrieved (q = 0.343,
p = 0.016), size of CLNM and number of metastatic CLNs
excised (q = 0.541, p \ 0.001) and size of CLNM and
metastatic CLN ratio (q = 0.387, p = 0.006). Group III
also tended to have higher proportion of patients receiving
RAI ablation after surgery than groups I and II (96.6 vs.
80.0 and 90.0 %, respectively), but this was not statistically
significant (p = 0.198). In the preablation period the
median sTg was similar, whereas in the postablation period
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FIG. 1 Cumulative disease-free survival curves of papillary thyroid
carcinoma between those with no central lymph node (CLN)
metastasis (pN0) (group I), with CLN micrometastases (pN1mic)
(group II), and with CLN macrometastases (pN1mac) (group III)
Lymph Node Metastasis as Predictor of Tg
the three groups (p = 0.012). The proportion of DsTg in
groups I and II was reduced from 60 to 17.5 and 55 to
15 %, respectively, after RAI ablation, whereas the pro-
portion in group III was reduced from 82.8 to 62.1 %. At
the time of analysis, all patients were alive. In groups I and
II, no patient developed LRR, whereas in group III, 2
developed ipsilateral lateral recurrences and 1 developed
bilateral lateral recurrence. These three recurrences devel-
oped at 19.4, 21.9 and 42.9 months after surgery. All three
recurrences had postablation DsTg 9 months after surgery,
and their median sTg level was 87.0 (range 9.7–103.0) lg/
L. The cumulative disease-free survival in groups I, II and
III were not significantly different (p = 0.151), and the
5-and 10-year disease-free survivals in group III were 85.1
and 85.1 %, respectively.
Table 2 shows the univariate analysis of clinicopathologic
factors for postablation DsTg (i.e.,[ 0.5 lg/mL). Age, gen-
der, clinical presentation and most tumor characteristics such
as multifocality, capsular invasion, extrathyroidal extension
and thyroiditis were similar between those with postablation
DsTg and with undetectable sTg. However, relative to those
with undetectable sTg, those with postablation DsTg had
larger median primary tumor size (2.0 vs. 1.5 cm, p = 0.018),
greater number of metastatic CLNs (2 vs. 1, p = 0.013),
higher CLN ratio (66.7 vs. 20.0 %, p = 0.003) and larger size
of CLNM (4.8 vs. 1.6 mm, p \ 0.001), but the proportion of
patients with metastatic CLN (pN1a) was similar between the
two groups (p = 0.114). When size of CLNM was catego-
rized into types of metastasis (pN0, pN1mic and pN1mac),
those with postablation DsTg had a significantly higher pro-
portion of pN1mac (67.7 vs. 10.9 %) but a lower proportion of
pN0 (20.6 vs. 60.0 %) and pN1mic (11.8 vs. 29.1 %) than
those with undetectable sTg (p = 0.002). There was a sig-
nificant direct correlation between the size of CLNM and
postablation sTg level (q = 0.428, p = 0.003), but such
correlation was not observed between size of CLNM and
preablation sTg (q = 0.264, p = 0.083).
Table 3 shows the multivariate analysis of clinicopath-
ologic risk factors for postablative DsTg 9 months after
surgery. Variables that were significant in the univariate
analysis were entered into the multivariate analysis. The
number of metastatic CLNs was not entered because it
significantly correlated with the CLN ratio (q = 0.896,
p \ 0.001), and the CLN ratio was shown to be a more
significant factor.21,22 Because the size and type of CLNM
were similar covariates, they were entered separately into
the multivariate analysis with CLN ratio and tumor size. In
the multivariate analysis, after adjusting for CLN ratio and
tumor size, size of CLNM (expressed as a continuous
variable) (odds ratio 1.56, 95 % confidence interval
1.09–2.24, p = 0.015) was the only independent factor for
postablation DsTg. Similarly, when the type of CLNM was
entered in the multivariate analysis with CLN ratio and
tumor size, relative to pN0 and pN1mic, pN1mac was
the only independent risk factor for postablation DsTg
(odds ratio 1.76, 95 % confidence interval 1.22–27.70,
p = 0.027).
DISCUSSION
Previous studies have found that size of LNM in the
lateral compartment is a significant risk factor for LRR,
distant metastasis and poor overall survival.8–11,14 Sugitani
et al. reported that for patients older than 50 years, LNM
C3 cm was an independent factor for cancer-specific sur-
vival from PTC.10 Similarly, it was observed that those
with clinically apparent or palpable LNM were at signifi-
cantly higher risk of developing LRR and distant
metastases than those with clinically inapparent or non-
palpable LNM.8–13 In fact, this was the rationale for
performing therapeutic selective neck dissection in the
lateral compartment and not prophylactic selective neck
dissection in patients with PTC.13 However, in comparison
to lateral selective neck dissection, pCND is associated
with lower surgical morbidity and can be performed within
the same incision as the thyroidectomy.23 In addition, it
provides more information regarding the nodal status as
required by the TNM and may lower LRRs.23 Several
studies confirmed that those who underwent pCND had a
significantly lower postsurgical sTg than those without
pCND. This perhaps suggests that pCND was able to
provide a more oncologically complete resection than
thyroidectomy alone by excising micrometastases harbored
in the central compartment.4–6 This hypothesis was sup-
ported by the fact that over 50 % of CLNs resected
harbored metastases.4–7 However, questions remain
regarding the size of these metastases and their importance
to patient outcomes. Given that the size of LNM in the
lateral compartment is a prognostic factor, we hypothesized
that the size of CLNM in pCND would also be a prognostic
factor, although this has not yet been demonstrated.
To ensure that our study only evaluated CLNs taken out
of pCND, 5 patients with CLNM C1 cm were excluded. In
our analysis, we found that even when the size of CLNM
was limited to \1 cm, it was an independent factor for
postablation DsTg 9 months after surgery. There was a
significant direct correlation between the size of CLNM
and postablation sTg level (q = 0.428, p = 0.003),
although not between size of CLNM and preablation sTg
(q = 0.264, p = 0.083). When the size of CLNM was
correlated with other clinicopathologic characteristics, we
observed that the size of CLNM was inversely correlated
with age (i.e., younger patients had larger-sized CLNM),
but this was directly correlated with greater number of
CLNs, metastatic CLNs and higher metastatic CLN ratio.
This latter association implied that larger-sized CLNM
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meant more extensive nodal involvement, at least within
the central compartment. This would account for the higher
rate of DsTg 9 months after surgery in the pN1mac group.
In the multivariate analysis, after adjusting for tumor size
and CLN ratio, patients with pN1mac were almost 6 times
more likely to have postablation DsTg than those with pN0.
Despite the small number of patients within each group, it
is worth noting that the odds ratio for pN1mic did not reach
statistical significance; this may imply that pN1mic did not
have the same significance level as pN1mac on postabla-
tion DsTg.
However, because the size of CLNM is a histopatho-
logic finding, its clinical application could only be limited
to the postsurgical management. Nevertheless, one possible
application would be to use it as a factor for deciding on
the dose of RAI ablation. Because most patients with either
TABLE 1 A comparison of
patient characteristics between
group I, II and III
Boldface signifies p-value
\0.05 or statistically significant
Continuous variables are
expressed as median (range);
categorical variables are
expressed as n (%)
PTC papillary thyroid
carcinoma, TNM 6th edition of
the tumor, node and metastasis
staging system, CLN central
lymph node, MACIS metastases,
age, completeness of surgery,




a CLN ratio = (no. of
metastatic CLNs/no. of CLNs
retrieved) 9 100
b Calculated on the basis of
number of nerves at risk
Characteristic Group I (n = 40) Group II (n = 20) Group III (n = 29) p-value
Age at operation (y) 52 (17–81) 48 (8–73) 43 (21–67) 0.003
Sex 0.814
Male 9 (22.5) 6 (30.0) 7 (24.1)
Female 31 (77.5) 14 (70.0) 22 (75.9)
Clinical presentation 0.310
Incidental 13 (32.5) 9 (45.0) 7 (24.1)
Symptomatic 27 (67.5) 11 (55.0) 22 (75.9)
Tumor characteristics
Tumor size (cm) 1.5 (0.3–3.8) 1.5 (0.3–4.0) 2.0 (0.5–6.0) 0.266
Multifocality 15 (37.5) 6 (30.0) 10 (34.5) 0.901
Capsular invasion 10 (25.0) 6 (30.0) 5 (17.2) 0.509
Extrathyroidal extension 14 (56.0) 4 (20.0) 6 (20.7) 0.331
Coexisting thyroiditis 8 (20.0) 4 (20.0) 7 (24.1) 0.378
Stage of PTC by TNM 0.198
Stage I/II 20 (50.0) 6 (30.0) 16 (55.2)
Stage III/IV 20 (50.0) 14 (70.0) 13 (44.8)
Size of CLN metastasis (mm) – 1.1 (0.1–1.8) 4.2 (2.0–6.9) \0.001
No. of CLNs retrieved 4 (3–18) 5.5 (3–9) 8 (3–21) 0.007
No. of metastatic CLNs excised – 1 (1–6) 4 (1–18) \0.001
Metastatic CLN ratio (%)a – 29.2 (12.5–100) 69.2 (12.5–100) 0.010
MACIS score 5.2 (3.2–8.0) 4.9 (3.3–12.0) 4.3 (3.2–8.9) 0.094
Postoperative hypocalcemia 0.739
Temporary 5 (12.5) 4 (20.0) 6 (20.7)
Permanent 1 (2.5) 0 (0.0) 1 (3.4)
Postoperative vocal cord palsyb 0.348
Temporary 0 (0.0) 1 (2.5) 2 (3.4)
Permanent 0 (0.0) 1 (2.5) 2 (3.4)
Radioiodine ablation 32 (80.0) 18 (90.0) 28 (96.6) 0.198
Anti-Tg antibody (titers) 0.399
B99 33 (82.5) 15 (75.0) 26 (89.7)
100–400 7 (17.5) 5 (25.0) 3 (10.3)
Preablation period
TSH level (mIU/L) 62 (34–339) 48 (35–226) 57 (37–250) 0.826
Stimulated Tg level (lg/L) 1.2 (\0.5–15.0) 0.9 (\0.5–114) 3.4 (\0.5–196) 0.141
No. of DsTg 24 (60.0) 11 (55.0) 24 (82.8) 0.070
Postablation period
TSH level (mIU/L) 87 (65–253) 91 (86–146) 68 (39–229) 0.595
Stimulated Tg level (lg/L) \0.5 (\0.5–4.7) \0.5 (\0.5–9.2) 0.8 (\0.5–110) 0.012
No. of DsTg 7 (17.5) 3 (15.0) 18 (62.1) 0.001
Locoregional recurrence 0 (0.0) 0 (0.0) 3 (10.3) 0.157
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pN1mic or pN1mac would receive at least one ablative
dose, it would be rational to have those with pN1mac
receiving a higher dose of ablation (instead of the standard
dose of 3 GBq) than those with pN1mic or pN0 when RAI
ablation is indicated. In our study, it was interesting to
observe that up to 42.5 % of patients with either pN0 or
pN1mic became athyroglobulinemic after 3 GBq of RAI
ablation, whereas only 20.7 % in the pN1mac group
became athyroglobulinemic. This means that the latter
group might perhaps benefit from a higher dose of RAI
ablation if athyroglobulinemia is the aim. If future studies
could confirm the size of CLNM as an independent factor
for outcomes, reporting the size of CLNM in the histopa-
thology reports could become important.
Despite these findings, we acknowledge shortcomings
with our study, including the relatively small number of
patients within each group and potential biases in the
selection for pCND. As a measure of outcome, some would
argue that a sTg of 0.5 lg/L might be set too low and a level
taken at 9 months after surgery might be too early. How-
ever, as shown previously, a sTg of\0.5 lg/L at 1 year had
a [98 % likelihood of identifying patients completely free
of disease at follow-up, and a sTg level taken at 1 year after
surgery was as good as a level taken 2–3 years after sur-
gery.24,25 Therefore, we believe sTg\0.5 lg/L at 9 months
after surgery is a reasonable surrogate for future recurrences.
Although not statistically significant, it is worth noting that
of the 3 LRR, all belonged to the pN1mac group and had
postablation DsTg with a median sTg level of 87.0 (range
9.7–103.0) lg/L. In contrast, none of the patients in pN0 or
pN1mic developed recurrences.
In conclusion, pN1mic accounted for 20 (22.5 %) of 89
patients undergoing pCND. Larger-sized CLNM was sig-
nificantly associated with younger age, greater number of
CLN retrieved, greater number of metastatic CLN excised,
higher metastatic CLN ratio and higher postablation sTg
TABLE 2 Univariate analysis of clinicopathologic risk factors for






(n = 34) (n = 55)
Age at operation
(years)
43 (21–78) 50 (17–81) 0.065
Sex 0.881
Male 9 (26.5) 13 (23.6)
Female 25 (73.5) 42 (76.4)
Clinical presentation 0.063
Incidental 5 (14.7) 24 (43.6)
Symptomatic 29 (85.3) 31 (56.4)
Tumor characteristics
Tumor size (cm) 2.0 (0.3–6.0) 1.5 (0.5–4.0) 0.018
Multifocality 16 (47.1) 15 (27.3) 0.125
Capsular invasion 11 (32.4) 10 (18.2) 0.390
Extrathyroidal
extension
15 (44.1) 9 (16.4) 0.445
Coexisting
thyroiditis




Stage I/II 19 (55.9) 23 (41.8)
Stage III/IV 15 (44.1) 32 (58.2)
No. of CLNs
retrieved
6 (3–21) 6 (4–18) 0.814
No. of metastatic
CLNs excised
2 (0–18) 1 (0–9) 0.013
Metastatic CLN
ratio (%)b
66.7 (0–100) 20 (0–100) 0.003
Metastatic CLN
(pN1a)
20 (58.8) 29 (52.7) 0.114
Size of CLN
metastasis (mm)




pN0 7 (20.6) 33 (60.0)
pN1mic 4 (11.8) 16 (29.1)
pN1mac 23 (67.6) 6 (10.9)
Boldface signifies p-value \0.05 or statistically significant
sTg stimulated thyroglobulin, PTC papillary thyroid carcinoma,
TNM 6th edition of the tumor, node and metastasis staging system,
CLN central lymph node, pN0 no central lymph node metastasis,
pN1mic micrometastasis (size B 2 mm), pN1mac macrometastasis
(size [ 2 mm)
a Continuous variables are expressed as median (range); categorical
variables are expressed as n (%)
b Metastatic CLN ratio = (no. of metastatic CLNs/no. of CLNs
retrieved) 9 100
TABLE 3 Multivariate analysis of clinicopathologic risk factors for









0.014 1.014 (0.990–1.039) 0.251
Primary tumor
size
0.389 1.476 (0.848–2.568) 0.168
Type of CLN metastasisb
pN0 1
pN1mic 0.949 2.583 (0.351–19.000) 0.351
pN1mac 1.760 5.814 (1.221–27.697) 0.027
Boldface signifies p-value \0.05 or statistically significant
CLN central lymph node, pN0 no CLN metastasis, pN1mic micro-
metastasis (size B 2 mm), pN1mac macrometastasis (size [ 2 mm)
a Metastatic CLN ratio = (no. of metastatic CLNs/no. of CLNs
retrieved) 9 100
b When size of CLN metastasis was entered instead, the odds ratio
became 1.564 (95 % confidence interval 1.092–2.241), p = 0.015
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level. Tumor size, metastatic CLN ratio and size of CLNM
were significantly associated with postablation DsTg, but
only size of CLNM turned out to be an independent factor
for postablation DsTg. Patients with pN1mac were almost
6 times more likely to have postablation DsTg than those
with pN0 or pN1mic.
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